Retrospective pharmaceutical financial benefits and cost avoidance analysis of clinical trial participation in the Australian haematology setting.
Kelvin TruongYiu Lam KwanLucia NigroAdmir HuseincehajicJudith TrotmanPublished in: Internal medicine journal (2020)
Pharmaceutical financial benefit is a previously unquantified aspect of clinical trial participation, its assigned value reflecting a measure of the quality and quantity of life delivered to patients. These data, albeit from a single discipline and institution, suggest that financial benefit represents a greater value than cost avoidance, and that its inclusion in cost-analyses may better reflect the monetary benefits of accessing efficacious pharmaceutical agents through clinical trials.
Keyphrases
- clinical trial
- phase ii
- end stage renal disease
- physical activity
- open label
- chronic kidney disease
- newly diagnosed
- ejection fraction
- double blind
- study protocol
- phase iii
- prognostic factors
- randomized controlled trial
- childhood cancer
- affordable care act
- electronic health record
- quality improvement
- cross sectional
- health insurance
- deep learning